HEPATOCELLULAR CARCINOMA

This early-stage trial tests a new RNA-based drug called YMN-A02 in 10 adults with advanced liver cancer that has not responded to standard treatments. The drug aims to boost the immune system by blocking two key pathways that help tumors hide. The main goal is to check safety an…

This study tests whether adding radiotherapy to a mix of immunotherapy (QL1706) and a targeted drug (bevacizumab) can shrink liver tumors enough to allow surgery. It involves 60 adults with liver cancer that cannot be removed surgically and has not spread. The goal is to see if t…

This study tests a treatment for liver cancer that cannot be removed by surgery. It combines tiny drug-coated beads placed into the liver's blood vessels with a targeted pill called Donafenib. The goal is to see if this approach can shrink tumors and help patients live longer wit…

This early-phase study looks at whether adding peginterferon alfa-2β to standard antiviral drugs can help people with hepatitis B-related liver cancer stay cancer-free longer after surgery. About 156 adults aged 18–65 will receive either the combination or antivirals alone. Resea…

This pilot study tests whether adding immunotherapy drugs (cemiplimab with or without fianlimab) after a type of radiation (Y90) can help control liver cancer in 20 adults. The goal is to slow or stop the cancer from growing. Participants will be randomly assigned to one of two t…

This early-stage trial tests a new treatment for adults with solid tumors that have come back or not responded to standard therapy. The treatment uses a patient's own immune cells, modified in a lab to better recognize and attack cancer cells that have a specific marker called GP…

This study tests whether giving a combination of drugs (sintilimab, bevacizumab, and chemotherapy) before surgery can lower the chance of liver cancer coming back in patients with high-risk features. About 100 adults with resectable liver cancer and high-risk factors will be rand…

This study is for people with advanced liver cancer who have already received two immunotherapy drugs (tremelimumab and durvalumab) and are now on durvalumab alone. Participants will add an experimental drug called zanzalintinib to their durvalumab treatment. The goal is to see i…

This early-stage trial tests a new drug called MRG006A combined with standard immune-boosting and targeted therapies for people with advanced liver cancer that cannot be removed by surgery. The study aims to find the safest dose and check if the combination shrinks tumors. About …

This study tests whether adding a three-drug pill regimen to a standard liver cancer procedure (TACE) helps people with liver cancer that cannot be surgically removed live longer compared to the usual approach of TACE plus targeted therapy and immunotherapy. About 222 adults who …

This early-stage study tests a new drug called FXB0871 in about 138 adults with advanced solid tumors, including lung and liver cancers that have stopped responding to standard treatments. The goal is to find a safe dose and see if the drug can shrink tumors. The study is not yet…

This study looks at whether giving a mix of local treatments (like radiation or chemo directly to the tumor) and drugs that target blood vessels and the immune system can shrink liver cancers enough for patients to qualify for a liver transplant. About 300 patients will be includ…

This study tests a radiation treatment called Yttrium-90 for people with liver cancer that cannot be surgically removed. About 64 adults with one or two small tumors will receive this treatment through a tiny tube into the liver's blood vessels. The goal is to see how well it shr…

This early-stage trial tests a new drug called TB511, alone or with pembrolizumab, in people with advanced solid tumors (lung, prostate, colorectal, or liver cancer) that stopped responding to standard treatments. The study has two parts: first, finding the safest dose of TB511 a…

This study looks back at medical records of 300 people with liver cancer that cannot be removed by surgery. The goal is to see if combining local treatments (like TACE or radiation) with targeted drugs and immunotherapy can shrink the tumors enough to allow surgery. Researchers w…

This study tests a combination of three drugs (gecacitinib, donafenib, and a PD-1 inhibitor) as a second treatment for people with advanced liver cancer that got worse after initial immunotherapy. About 35 adults will receive this triple therapy to see if it can shrink tumors and…

This study tests a treatment called multimodal thermal therapy (MTT) that uses both freezing and heating to destroy liver tumors. The goal is to see if it can control the cancer and also activate the body's immune system to fight it. The trial will include 120 adults with liver c…

This study tests whether adding an experimental drug called GKL-006 to the standard TACE procedure can shrink liver tumors that cannot be surgically removed. About 48 adults with unresectable hepatocellular carcinoma will be randomly assigned to receive either TACE alone or TACE …

This study tests a new first-line treatment for people with advanced liver cancer that cannot be removed by surgery. The treatment combines a procedure that delivers chemotherapy directly to the tumor (TACE) with two drugs that boost the immune system and block blood vessel growt…

This study tests a new treatment for people with advanced liver cancer that cannot be surgically removed. The treatment combines low doses of two drugs (bevacizumab and atezolizumab) with a procedure that delivers chemotherapy directly to the liver. The goal is to see if this app…

This is the first human study of an experimental oral drug called ACC-1898 for adults with advanced solid tumors that have stopped responding to standard treatments. The main goals are to find a safe dose and understand how the body processes the drug. Participants will take dail…

This study tests a new way to use contrast-enhanced ultrasound (CEUS) to see if liver cancer treatment (ablation) worked completely. Researchers will compare CEUS results with standard CT or MRI scans in 200 adults. If accurate, this method could reduce the need for radiation or …

This study looks at whether adding nanocrystalline megestrol acetate to standard treatment can improve appetite and body mass index (BMI) in people with advanced liver cancer who are experiencing cachexia (severe weight loss and muscle wasting). About 68 participants will be rand…

This study uses a special MRI machine to take pictures of the liver using phosphorus and sodium signals. Researchers will compare images from people with liver cancer and healthy volunteers to see if these scans can help tell them apart. The goal is to learn more about how liver …

This study will test whether an artificial intelligence (AI) model can accurately predict how well liver cancer patients respond to a combination of treatments: TACE (a procedure that blocks blood flow to the tumor), immunotherapy, and targeted therapy. Researchers will collect d…

This study will follow 1,000 adults who have liver or bile duct surgery at San Jacopo Hospital in Pistoia. Researchers will track complications, survival, and cancer recurrence for up to 5 years. The goal is to better understand how patients recover and their long-term outcomes a…

This study looks back at medical records of 200 liver cancer patients in Austria to see if getting an mRNA COVID-19 vaccine within three months before starting immunotherapy improves their response to cancer treatment. Researchers will also check if vaccination affects survival o…